Bird Rock Bio is a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators. Backed by leading biotechnology venture investors, our strategy leverages biologic targets with substantial human proof of mechanism for the development of novel, best-in-class therapeutic antibodies with significant clinical and commercial differentiation.
Home
News
- September 13, 2018
Bird Rock Bio Completes Clinical Trial of Nimacimab in Patients with Fatty Liver Disease - September 10, 2018
Bird Rock Bio, Inc. Gains Approval for Use of Generic Drug Name Nimacimab (RYI-018), a Monoclonal Antibody for the Treatment of NASH, Diabetic Nephropathy and Other Diseases - June 5, 2017
Bird Rock Bio Completes Single Ascending Dose Human Clinical Trial for RYI-018; Generates Safety, Tolerability, and Pharmacokinetics Data; Prepares To Initiate Study in Non-Alcoholic Fatty Liver Disease Patients